Natural and pharmacological regulation of telomerase

Nucleic Acids Research

Volumn 30, Issue 4, 2002, Pages 839-865

  Mergny, Jean Louis ^a   Riou, Jean François ^b   Mailliet, Patrick ^c   Teulade Fichou, Marie Paule ^d   Gilson, Eric ^e  

^a MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^c SANOFI   (France)

^d CNRS   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; AMIDOANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA RUBRAMYCIN; BIBR 1532; CARBOXYCLIC AMIDE DERIVATIVE; CATHECHIN DERIVATIVE; CELL DNA; CISPLATIN; DIBENZOPHENANTHROLINE DERIVATIVE; DIDANOSINE; ETHIDIUM; ETOPOSIDE; FJ 5002; INDOLE DERIVATIVE; ISOTHIAZOLONE DERIVATIVE; NUCLEOSIDE ANALOG; OLIGONUCLEOTIDE; PHOSPHORAMIDIC ACID DERIVATIVE; PORPHYRIN DERIVATIVE; RHODOCYANINE DERIVATIVE; RIBOZYME DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE INHIBITOR; TELOMESTATIN; THIAZINE DERIVATIVE; TRIAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

CELL DIVISION; CHROMOSOME; CHROMOSOME STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME REGULATION; ENZYME SPECIFICITY; EUKARYOTE; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOMATIC CELL; TELOMERE; TUMOR CELL;

EUKARYOTA;

EID: 0037082423     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/30.4.839     Document Type: Review

References (393)

1. Normal human chromosomes have long G-rich telomeric overhangs at one end
2. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening
3. The terminal DNA structure of mammalian chromosomes
4. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon
5. Telomere shortening is associated with cell division in vitro and in vivo
6. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts
7. Reverse transcriptase motifs in the catalytic subunit of telomerase
8. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats
9. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization
10. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types
11. Telomerase catalytic subunit homologs from fission yeast and human
12. The RNA component of human telomerase
13. DNA damage and repair in telomeres: Relation to aging
14. Telomeres, telomerase and cancer: An up-date
15. Extension of life-span by introduction of telomerase into normal human cells
16. Telomerase activity is sufficient to allow transformed cells to escape from crisis
17. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
18. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase
19. Inhibition of telomerase limits the growth of human cancer cells
20. Creation of human tumour cells with defined genetic elements
21. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
22. The hallmarks of cancer
23. Telomerase activity associated with acquisition of malignancy in human colorectal cancer
24. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis
25. Short dysfunctional telomeres impair tumorigenesis in the INK4a(Delta 2/3) cancer-prone mouse
26. Longevity of lobsters is linked to ubiquitous telomerase expression
27. Telomerase regulation during entry into the cell cycle in normal human T cells
28. Telomere lengthening and telomerase activation during human B cell differentiation
29. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
30. Telomerase activity in human endometrium
31. Suppression of telomerase activity in HL60 cells after treatment with differentiating agents
32. Differentiation of immortal cells inhibits telomerase activity
33. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines
34. Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells
35. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation
36. Evidence for UV-associated activation of telomerase in human skin
37. Telomerase is not an epidermal stem cell marker and is downregulated by calcium
38. Modulation of telomerase activity by zinc in human prostatic and renal cancer cells
39. Interferon down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells
40. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells
41. Estrogen activates telomerase
42. Autocrine transforming growth factor beta suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells
43. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT
44. Reconstitution of human telomerase activity in vitro
45. Mechanism of telomerase induction during T cell activation
46. Alternative pathways for the extension of cellular life span: Inactivation of p53/pRb and expression of telomerase
47. Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization
48. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (HTERT)
49. The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter
50. Telomere position effect in human cells
51. Frequent amplification of the telomerase reverse transcriptase gene in human tumors
52. Regulation of human telomerase activity: Repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity
53. Activity, function and gene regulation of the catalytic subunit of telomerase (HTERT)
54. Rb and E2F-1 regulate telomerase activity in human cancer cells
55. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene
56. NF-kappa B regulates transcription of the mouse telomerase catalytic subunit
57. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (HTERT) gene promoter: Possible role of MZF-2 in transcriptional repression of hTERT
58. Myc activates telomerase
59. hTERT expression correlates with myc over-expression in human prostate cancer
60. The correlation of TERT expression with c-myc expression in cervical cancer
61. Direct activation of TERT transcription by c-MYC
62. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation
63. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells
64. Spl cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (HTERT)
65. Cloning of human telomerase catalytic subunit (HTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells
66. Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line
67. Arsenic inhibition of telomerase transcription leads to genetic instability
68. Identification of Mad as a repressor of the human telomerase (HTERT) gene
69. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells
70. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1
71. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription
72. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells
73. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells
74. Telomerase activation by histone deacetylase inhibitor in normal cells
75. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression
76. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene
77. Methylation of the human telomerase gene CpG island
78. Constitutive and regulated expression of telomerase reverse transcriptase (HTERT) in human lymphocytes
79. The hTERT alpha splice variant is a dominant negative inhibitor of telomerase activity
80. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity
81. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (HTERT) in normal and neoplastic ovary, endometrium, and myometrium
82. Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma
83. Functional multimerization of the human telomerase reverse transcriptase
84. Human telomerase contains two cooperating telomerase RNA molecules
85. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression
86. Hsp90 levels affect telomere length in yeast
87. Hsp90 a specialized but essential protein folding tool
88. Stable association of hsp90 and p23, but not hsp70, with active human telomerase
89. Cutting edge: Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation
90. Involvement of 14-3-3 proteins in nuclear localization of telomerase
91. Downregulation of 14-3-3 sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes
92. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture
93. Telomerase is controlled by protein kinase C alpha in human breast cancer cells
94. Telomerase is regulated by protein kinase C-zeta in human nasopharyngeal cancer cells
95. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells
96. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit
97. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase
98. MEC1-dependent redistribution of the Sir3 silencing protein from telomeres to DNA double-strand breaks
99. Relocalization of telomeric Ku and SIR proteins in response to DNA strand breaks in yeast
100. Regulation of catalytic activity and processivity of human telomerase
101. Analysis of telomerase processivity: Mechanistic similarity to HIV-1 reverse transcriptase and role in telomere maintenance
102. Enzymatic activity of endogenous telomerase associated with intact nuclei from human leukemia CEM cells
103. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita
104. A telomerase component is defective in the human disease dyskeratosis congenita
105. Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita
106. Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle
107. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels
108. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences
109. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter
110. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end
111. In vitro assembly of human H/ACA small nucleolar RNPs reveals unique features of U17 and telomerase RNAs
112. Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10
113. Stable expression in yeast of the mature form of human telomerase RNA depends on its association with the box H/ACA small nucleolar RNP proteins Cbf5p, Nhp2p and Nop10p
114. Heterogeneous nuclear ribonucleoproteins C1 and C2 associate with the RNA component of human telomerase
115. The La antigen associates with the human telomerase ribonucleoprotein and influences telomere length in vivo
116. Identification of two RNA-binding proteins associated with human telomerase RNA
117. Human telomerase RNA-protein interactions
118. Functionally interacting telomerase RNAs in the yeast telomerase complex
119. Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro
120. Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions
121. RNA binding domain of telomerase reverse transcriptase
122. Identification of functional domains and dominant negative mutations in vertebrate telomerase RNA using an in vivo reconstitution system
123. Dynamics of telomere length variation in Tetrahymena thermophila
124. Telomere length regulation
125. Characterization of two telomeric DNA processing reactions in Saccharomyces cerevisiae
126. C-terminal truncation of RAP1 results in the deregulation of telomere size, stability and function in Saccharomyces cerevisiae
127. Runaway telomere elongation caused by telomerase RNA gene mutations
128. The cohering telomeres of Oxytricha
129. Formation of parallel four-stranded complexes by guanine-rich motifs in DNA and its applications for meiosis
130. Telomeric DNA dimerizes by formation of guanine tetrads between hairpin loops
131. G-quartet structures in telomeric DNA
132. Inhibition of telomerase by G-quartet DNA structures
133. In vitro generated antibodies specific for telomeric guanine quadruplex DNA react with Stylonychia lemnae macronuclei
134. Following G-quartet formation by UV-spectroscopy
135. In vitro properties of the conserved mammalian protein hnRNP D suggest a role in telomere maintenance
136. Intramolecular folding of a fragment of the cytosine-rich strand of telomeric DNA into an i-motif
137. Human telomeric C-strand tetraplexes
138. The Saccharomyces CDC13 protein is a single-strand TG(1-3) telomeric DNA-binding protein in vitro that affects telomere behavior in vivo
139. Telomere-binding and Stn1p-interacting activities are required for the essential function of Saccharomyces cerevisiae Cdc13p
140. Sir proteins, Rif proteins and Cdc13p bind Saccharomyces telomeres in vivo
141. Cdc13p: A single-strand telomeric DNA binding protein with a dual role in yeast telomere maintenance
142. Est1 and Cdc13 as comediators of telomerase access
143. Cdc13 cooperates with the yeast Ku proteins and Stn1 to regulate telomerase recruitment
144. Cdc13 both positively and negatively regulates telomere replication
145. Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases alpha and delta
146. Cell cycle restriction of telomere elongation
147. Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase
148. Pot1, the putative telomere end-binding protein in fission yeast and humans
149. Telomere proteins: Specific recognition and protection of the natural termini of Oxytricha macronuclear DNA
150. Involvement of HIV-I nucleocapsid protein in the recruitment of reverse transcriptase into nucleoprotein complexes formed in vitro
151. The beta-subunit of Oxytricha telomere-binding protein promotes G-quartet formation by telomeric DNA
152. Nucleocapsid protein of human immunodeficiency virus as a model protein with chaperoning functions and as a target for antiviral drugs
153. Addition of telomere-associated HeT DNA sequences "heals" broken chromosome ends in Drosophila
154. Programmed translational frameshifting in a gene required for yeast telomere replication
155. Yeast Ku as a regulator of chromosomal DNA end structure
156. Yeast Ku protein plays a direct role in telomeric silencing and counteracts inhibition by Rif proteins
157. Mammalian Ku86 protein prevents telomeric fusions independently of the length of TTAGGG repeats and the G-strand overhang
158. TEL1, a gene involved in controlling telomere length in S. cerevisiae, is homologous to the human ataxia telangiectasia gene
159. Reduced telomere length in ataxia-telangiectasia fibroblasts
160. Stn1, a new Saccharomyces cerevisiae protein, is implicated in telomere size regulation in association with Cdc13
161. Ten1 functions in telomere end protection and length regulation in association with Stn1 and Cdc13
162. Cdc13 delivers separate complexes to the telomere for end protection and replication
163. Evidence for a new step in telomere maintenance
164. The Saccharomyces telomere-binding protein Cdc13p interacts with both the catalytic subunit of DNA polymerase alpha and the telomerase-associated Est1 protein
165. CDC17: An essential gene that prevents telomere elongation in yeast
166. The function of DNA polymerase alpha at telomeric G-tails is important for telomere homeostasis
167. Coordinate regulation of G- and C-strand length during new telomere synthesis
168. Identification of the single-strand telomeric DNA binding domain of the Saccharomyces cerevisiae Cdc13 protein
169. Control of telomere growth by interactions of RAP1 with the most distal telomeric repeats
170. A protein-counting mechanism for telomere length regulation in yeast
171. Progressive cis-inhibition of telomerase upon telomere elongation
172. A novel Rap1p-interacting factor, Rif2p, cooperates with Rif1p to regulate telomere length in Saccharomyces cerevisiae
173. Regulation of telomere length and function by a Myb-domain protein in fission yeast
174. A human telomeric protein
175. The telobox, a Myb-related telomeric DNA binding motif found in proteins from yeast, plants and human
176. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2
177. Telomeric localization of TRF2, a novel human telobox protein
178. TRF1 binds a bipartite telomeric site with extreme spatial flexibility
179. Taz1p and Teb1p, two telobox proteins in Schizosaccharomyces pombe, recognize different telomere-related DNA sequences
180. Control of telomere length by the human telomeric protein TRF1
181. Control of human telomere length by TRF1 and TRF2
182. TIN2, a new regulator of telomere length in human cells
183. TRF2 protects human telomeres from end-to-end fusions
184. DNA structure-specific nuclease activities in the Saccharomyces cerevisiae Rad50 Mre11 complex
185. Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres
186. Telomeres and their control
187. The rate of telomere sequence loss in human leukocytes varies with age
188. Identification of human Rap1: Implications for telomere evolution
189. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres
190. Tankyrase promotes telomere elongation in human cells
191. TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression
192. Functions of poly(ADP-ribose) polymerase in controling telomere length and chromosomal stability
193. Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase deficient mice and primary cells despite increased chromosomal instability
194. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor
195. Interaction between Set1p and checkpoint protein Mec3p in DNA repair and telomere functions
196. MRT-2 checkpoint protein is required for germline immortality and telomere replication in C. elegans
197. Inhibition of telomeres and telomerase. Seeking for new anticancer drugs
198. Human telomerase inhibitors
199. Telomeres and telomerase: Targets for cancer chemotherapy?
200. The telomerase challenge-an unusual problem in drug discovery
201. Telomerase targeting in cancer treatment: New developments
202. Recent advances in the development of telomerase inhibitors for the treatment of cancer
203. Telomerase inhibitors
204. Telomerase inhibitors: Targeting the vulnerable end of cancer
205. Telomerase inhibitors
206. Specific association of human telomerase activity with immortal cells and cancer
207. Increased sensitivity and reproducibility of TRAP assay by avoiding direct primers interaction
208. Detection of telomerase activity in human carcinomas using a TRAP-ELISA method: Correlation with hTR and hTERT expression
209. Detection of telomerase activity in hepatocellular carcinoma by fluorescence-based TRAP method
210. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity
211. Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust 'TRAP' assay
212. Detection of telomerase activity by combination of TRAP method and scintillation proximity assay (SPA)
213. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro
214. The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena
215. Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates
216. Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside nucleoside triphosphate analogs: Potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate
217. Preferential incorporation of 3′-azido-2′,3′-dideoxythymidine (AZT) in telomeric sequences of CHO cells
218. Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment
219. Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3′-azido-2′-3′-dideoxythymidine
220. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines
221. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines
222. Chronic in vitro exposure to 3′-azido-2′,3′-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells
223. Recognition of 2′-deoxy-L-ribonucleoside 5′-triphosphates by human telomerase
224. Interaction of deoxyguanosine nucleotide analogs with human telomerase
225. Inhibition of human telomerase by rubromycins: Implication of spiroketal system of the compounds as an active moiety
226. A highly selective telomerase inhibitor limiting human cancer cell proliferation
227. Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro
228. The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function
229. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity
230. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase
231. Secondary structure of vertebrate telomerase RNA
232. Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation
233. Inhibition of human telomerase activity by peptide nucleic acids
234. Identification of determinants for inhibitor binding within the RNA acti site of human telomerase using PNA scanning
235. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells
236. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
237. Inhibition of human telomerase by PNA-cationic peptide conjugates
238. Inhibition of human telomerase by 2′-O-methyl-RNA
239. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
240. Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: Effect of length, phosphorothioate substitution and time inside cells
241. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
242. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells
243. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component
244. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas
245. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53
246. Telomerase inhibitors-oligonucleotide phosphoramidates as potential therapeutic agents
247. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells
248. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells
249. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells
250. Targeting telomerase via its key RNA/DNA heteroduplex
251. Sequence and structural selectivity of nucleic acid binding ligands
252. Molecular recognition of a RNA:DNA hybrid structure
253. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation
254. Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability
255. Telomerase-associated protein TEP1 is not essential for telomerase activity or telomere length maintenance in vivo
256. The telomerase/vault-associated protein TEP1 is required for vault RNA stability and its association with the vault particle
257. Functional requirement of p23 and Hsp90 in telomerase complexes
258. Telomerase activity reconstituted in vitro with purified human telomerase reverse transcriptase and human telomerase RNA component
259. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function
260. Telomere shortening by cisplatin in yeast nucleotide excision repair mutant
261. Platination of the (T2G4)4 telomeric sequence: A structural and crosslinking story
262. Inhibition of telomerase activity by cisplatin in human testicular cancer cells
263. Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents
264. DNA topoisomerase II cleavage of telomeres in vitro and in vivo
265. A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage
266. DNA topoisomerase inhibitors induce reversible senescence in normal human fibroblasts
267. Telomerase activity as a measure for monitoring radiocurability of tumor cells
268. Effects of irradiation on telomerase activity in human lymphoma and myeloma cell lines
269. G-overhang dynamics at Tetrahymena telomeres
270. Mammalian telomeres end in a large duplex loop
271. An eclectic DNA structure adopted by human telomeric sequence under superhelical stress and low pH
272. Solution structure of a parallel-stranded tetraplex formed by d(TG(4)T) in the presence of sodium ions by nuclear magnetic resonance spectroscopy
273. Solution structure of a parallel-stranded G-quadruplex DNA
274. d(G(3)T(4)G(3)) forms an asymmetric diagonally looped dimeric quadruplex with guanosine 5′-syn-syn-anti and 5′-syn-anti-anti N-glycosidic conformations
275. The effect of sodium, potassium and ammonium ions on the conformation of the dimeric quadruplex formed by the Oxytricha nova telomere repeat oligonucleotide d(G(4)T(4)G(4))
276. Quadruplex structure of oxytricha telomeric DNA oligonucleotides
277. Solution structure of the human telomeric repeat d[AG3(T2AG3)3] G-tetraplex
278. G-quadruplex DNA as a target for drug design
279. A novel yeast gene product, G4p1, with a specific affinity for quadruplex nucleic acids
280. A protein from Tetrahymena thermophila that specifically binds parallel-stranded G4-DNA
281. Yeast meiosis-specific protein Hop1 binds to G4 DNA and promotes its formation
282. Interaction of human DNA topoisomerase I with intermolecular G-quartet structures
283. The identification and characterization of a G4-DNA resolvase activity
284. The SV40 large T-antigen helicase can unwind four stranded DNA structures linked by G-quarters
285. The Saccharomyces cerevisiae Sgs1 helicase efficiently unwinds G-G paired DNAs
286. The yeast telomere-binding protein RAP1 binds to and promotes the formation of DNA quadruplexes in telomeric DNA
287. The Saccharomyces cerevisiae WRN homolog Sgs1p participates in telomere maintenance in cells lacking telomerase
288. Recombination-mediated lengthening of terminal telomeric repeats requires the Sgs1 DNA helicase
289. SGS1 is required for telomere elongation in the absence of telomerase
290. G-quadruplex DNA: A target for drug design
291. The development of telomerase inhibitors: The G-quartet approach
292. Triple helix specific ligands
293. Inhibition of human telomerase by a G-quadruplex-interactive compound
294. Cationic porphyrins as telomerase inhibitors: The interaction of tetra (N-methyl-4-pyridyl) porphyrin with quadruplex DNA
295. Porphyrin binding to quadrupled T4G4
296. Fluorescent dyes specific for quadruplex DNA
297. Interactions of TMPyP4 and TMPyP2 with quadruplex DNA. Structural basis for the differential effects on telomerase inhibition
298. NMR-based model of a telomerase inhibiting compound bound to G-quadruplex DNA
299. Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones
300. 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase
301. A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline
302. Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors
303. Telomerase inhibitors based on quadruplex ligands selected by a fluorescent assay
304. Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes
305. Arylamine derivatives and their use as antitelomerase agents
306. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with g-quadruplexes
307. Fluorescence resonance energy transfer as a probe for G-quartet formation by a telomeric repeat
308. Cell senescence and telomere shortening induced by a new series of specific quadruplex DNA ligands
309. Interaction of an acridine dimer with DNA quadruplex structures
310. Selective interactions of cationic porphyrins with G-quadruplex structures
311. Intercalative G-tetraplex stabilization of telomeric DNA by a cationic porphyrin
312. Design and synthesis of the G-quadruplex-specific cleaving reagent perylene-EDTA.iron(II)
313. Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule
314. Fluorescence in situ hybridization with a synthetic (T(2)AG(3))(n) polynucleotide detects several intrachromosomal telomere-like repeats on human chromosomes
315. Human intrachromosomal telomeric-like repeats: Sequence organization and mechanisms of origin
316. Tetramerization of an RNA oligonucleotide containing a GGGG sequence
317. The stability of DNA and RNA G-quartets
318. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif
319. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function
320. Inhibition of unwinding of G-quadruplex structures by Sgs1 helicase in the presence of N,N′-bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-interactive ligand
321. Substrate-specific inhibition of RecQ helicase
322. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells
323. 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation
324. The cytotoxic effects of single-stranded telomere mimics on OMA-BL1 cells
325. Specific targeting of insect and vertebrate telomeres with pyrrole and imidazole polyamides
326. Use of transcriptional regulatory sequences of telomerase (HTER and hTERT) for selective killing of cancer cells
327. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers
328. A novel telomerase-specific gene therapy: Gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter
329. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter
330. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters
331. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
332. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
333. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
334. Telomerase reverse transcriptase: Candidate for "universal cancer vaccine"?
335. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes
336. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing
337. New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines
338. Development of novel telomerase inhibitors based on a bisindole unit
339. Telomerase inhibition, telomere shortening and senescence of cancer cells by tea catechins
340. Inhibition of human telomerase activity by alterperylenol
341. Diazaphilonic acid, a new azaphilone with telomerase inhibitory activity
342. FJ5002: A potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis
343. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus
344. Ultraviolet irradiation- and dimethyl sulfoxide-induced telomerase activity in ovarian epithelial cell lines
345. A novel mechanism for telomere size control in Saccharomyces cerevisiae
346. Intrachromatid excision of telomeric DNA as a mechanism for telomere size control in Saccharomyces cerevisiae
347. Long term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: An in vitro study
348. Alternative lengthening of telomeres in human cells
349. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
350. Telomere maintenance by recombination in human cells
351. Telomerase can inhibit the recombination based pathway of telomere maintenance in human cells
352. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells
353. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids
354. A repressor function for telomerase activity in telomerase-negative immortal cells
355. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells
356. Telomere shortening is proportional to the size of the G-rich telomeric 3′-overhang
357. Molecular manifestations and molecular determinants of telomere capping
358. Telomerase RNA mutations in Saccharomyces cerevisiae alter telomerase action and reveal nonprocessivity in vivo and in vitro
359. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening
360. Telomere states and cell fates
361. Telomere dysfunction alters the chemotherapeutic profile of transformed cells
362. Short telomeres result in organismal hypersensitivity to ionizing radiation in mammals
363. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation
364. Telomere length abnormalities in mammalian radiosensitive cells
365. Expression of telomerase inhibits hydroxyl radical-induced apoptosis in normal telomerase negative human lung fibroblasts
366. Anti-apoptotic role of telomerase in pheochromocytoma cells
367. The catalytic subunit of telomerase protects neurons against amyloid beta-peptide-induced apoptosis
368. Up-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide
369. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse biology
370. Perspectives: Aging-when do telomeres matter?
371. Lack of replicative senescence in normal rodent glia
372. Role of p14ARF in replicative and induced senescence of human fibroblasts
373. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA
374. Essential role of mouse telomerase in highly proliferative organs
375. Telomerase inhibition in RenCa, a murine tumor cell line with short telomeres, by overexpression of a dominant negative mTERT mutant, reveals fundamental differences in telomerase regulation between human and murine cells
376. Mice without telomerase: What can they teach us about human cancer
377. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice
378. A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation
379. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis
380. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes
381. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans
382. Telomere dysfunction increases mutation rate and genomic instability
383. Saccharomyces telomeres acquire single-strand TG(1-3) tails late in S-phase
384. T-loops at trypanosome telomeres
385. All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3′ terminus
386. The terminal organization of macronuclear DNA in Oxytricha fallax
387. Telomeres of polytene chromosomes in a ciliated protozoan terminate in duplex DNA loops
388. An overhanging 3′ terminus is a conserved feature of telomeres
389. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells
390. Role for the related poly(ADP-ribose) polymerase tankyrase 1 and 2 at human telomeres
391. Protein kinase C inhibitors as novel anticancer drugs
392. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [I-131]MIBG and clonogenic cell kill
393. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954